Excessive Daytime Sleepiness Market Report 2026

The excessive daytime sleepiness market size has grown strongly in recent years. It will grow from $5.39 billion in 2025 to $5.9 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing prevalence of sleep disorders, rising awareness of sleep health impacts, growth in sleep clinic infrastructure, availability of pharmacological wake-promoting agents, expansion of diagnostic sleep testing services.

The excessive daytime sleepiness market size is expected to see strong growth in the next few years. It will grow to $8.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing demand for personalized sleep treatment plans, rising integration of digital therapeutics in sleep care, expansion of remote patient monitoring adoption, growing focus on preventive sleep healthcare, increasing investment in sleep medicine research. Major trends in the forecast period include increasing adoption of wearable sleep monitoring devices, growing use of combination therapy approaches, expansion of home-based sleep disorder management, rising focus on early diagnosis and screening programs, enhanced integration of digital sleep health platforms.

The increasing prevalence of obstructive sleep apnea (OSA) is expected to propel the growth of the excessive daytime sleepiness (EDS) market going forward. Obstructive sleep apnea is a sleep disorder marked by repeated breathing interruptions during sleep caused by upper airway obstruction, resulting in disrupted sleep patterns and reduced sleep quality. The incidence of obstructive sleep apnea is rising due to increasing obesity rates, as excess fat around the neck and throat narrows the airway and triggers breathing disturbances during sleep. Excessive daytime sleepiness is a frequent and debilitating symptom associated with obstructive sleep apnea and often persists in a substantial portion of patients, driving demand for targeted treatment and management options. For instance, in August 2026, according to the National Library of Medicine, a US-based medical library, approximately 76.6 million adults aged 30-69 in the United States are projected to be affected by obstructive sleep apnea by 2050. Therefore, the rising prevalence of obstructive sleep apnea is fueling the growth of the excessive daytime sleepiness market.

Leading companies operating in the excessive daytime sleepiness market are focusing on developing innovative solutions, such as central nervous system depressants, to improve wakefulness and enhance quality of life for patients. A central nervous system depressant is a substance that reduces nervous system activity, causing sedation, calmness, or sleep. For example, in September 2025, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, received approval from the FDA for sodium oxybate oral solution, which directly treats excessive daytime sleepiness (EDS) in narcolepsy patients. It enhances treatment continuity by facilitating virtual specialist consultations, remote prescription fulfillment, and improved patient reach in underserved regions, with the purpose of expanding access, improving affordability, and aligning established pharmacotherapy with evolving digital and telehealth-driven care models for excessive daytime sleepiness.

In October 2025, Alkermes plc, an Ireland-based biopharmaceutical company, acquired Avadel Pharmaceuticals plc for an undisclosed amount. Through this acquisition, Alkermes seeks to accelerate its entry into the sleep medicine market, diversify its product portfolio with the FDA-approved LUMRYZ therapy, and strengthen its capabilities in rare and central disorders of hypersomnolence. Avadel Pharmaceuticals plc is an Ireland-based commercial-stage biopharmaceutical company that provides treatments for excessive daytime sleepiness.

Major companies operating in the excessive daytime sleepiness market are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cleveland Clinic, EisAI Co. Ltd, Jazz Pharmaceuticals plc., Emory Healthcare Inc., Alkermes plc., Fisher & Paykel Healthcare Corporation Limited, Harmony Biosciences Holdings Inc., Medanta, Axsome Therapeutics Inc., Compumedics Limited, BIOPROJET, Apnimed Inc., Nox Health Inc., Somnogen Canada Inc., Suven Life Sciences Limited, Theranexus, XWPharma, NLS Pharmaceutics AG.

Tariffs are impacting the excessive daytime sleepiness market by increasing costs of imported CPAP devices, wearable monitoring equipment, diagnostic tools, and pharmaceutical manufacturing inputs. Healthcare providers in North America and Europe are most affected due to reliance on imported medical devices, while Asia-Pacific faces higher costs for exporting sleep therapy equipment. These tariffs are increasing treatment costs and slowing device replacement cycles. However, they are also encouraging domestic medical device manufacturing, regional supply chain development, and innovation in cost-efficient sleep monitoring and therapy solutions.

The excessive daytime sleepiness market research report is one of a series of new reports that provides excessive daytime sleepiness market statistics, including excessive daytime sleepiness industry global market size, regional shares, competitors with a excessive daytime sleepiness market share, detailed excessive daytime sleepiness market segments, market trends and opportunities, and any further data you may need to thrive in the excessive daytime sleepiness industry. This excessive daytime sleepiness market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Excessive daytime sleepiness is a health condition marked by a continual difficulty in staying awake and alert during normal waking hours. It is frequently linked to underlying sleep disorders, neurological issues, or lifestyle factors that disturb normal sleep patterns. This condition can substantially affect daily functioning, cognitive abilities, and overall quality of life.

The key treatment types of excessive daytime sleepiness include pharmacological treatment, behavioral therapy, continuous positive airway pressure therapy, lifestyle modification programs, and combination therapies. Pharmacological treatment refers to the use of medications to reduce sleepiness and improve wakefulness in affected patients. These treatments are applied using diagnostic methods such as polysomnography, multiple sleep latency tests, actigraphy, clinical evaluation, and questionnaire-based assessments. The types of disorder include narcolepsy, obstructive sleep apnea, insomnia, circadian rhythm disorders, idiopathic hypersomnia, restless legs syndrome, and other disorders. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, and the end users are hospitals, sleep clinics, ambulatory surgical centers, and home care settings.

The excessive daytime sleepiness market consists of revenues earned by entities by providing services such as sleep disorder diagnosis and assessment, sleep monitoring and polysomnography services, patient counseling and behavioral therapy sessions, and treatment planning and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The excessive daytime sleepiness market also includes sales of stimulants, modafinil and armodafinil, sodium oxybate, continuous positive airway pressure (CPAP) devices, wearable sleep monitoring devices, and other supportive medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.